DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

216 Furchgott RF. Endothelium-derived relaxing factor: Discovery,
early studies, and identification as nitric oxide. Biosci Rep,
1999, 19:235–251.
Gordon JL. Extracellular ATP: Effects, sources and fate.
Biochem J, 1986, 233:309–319.
Gutkind JS. The pathways connecting G protein–coupled
receptors to the nucleus through divergent mitogenactivated
protein kinase cascades. J Biol Chem, 1998, 273:
1839–1842.
Hanyaloglu A, von Zastrow M. Regulation of GPCRs by endocytic
membrane trafficking and its potential implications.
Annu Rev Pharmacol Toxicol, 2008, 48:537–568.
Hein L, Schmitt JP. α 1
-Adrenoceptors in the heart: Friend or foe?
J Mol Cell Cardiol, 2003, 35:1183–1185.
Hieble J P. Subclassification and nomenclature of α- and
β-adrenoceptors. Curr Top Med Chem, 2007, 7:129–134.
Hilal-Dandan R, Villegas S, Gonzalez A, Brunton L. The quasiirreversible
nature of endothelin binding and G protein-linked
signaling in cardiac myocytes. J Pharmacol Exp Ther, 1997,
281:267–273.
Hille B. Ionic Channels of Excitable Membranes, 2d ed. Sinauer
Associates, Sunderland, MA, 1992.
Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase
as a potential therapeutic target. Annu Rev Pharmacol
Toxicol, 1999, 39:191–220.
Hökfelt T, Broberger C, Xu ZQ, et al. Neuropeptides: An
overview. Neuropharmacology, 2000, 39:1337–1356.
Hutchins C. Three-dimensional models of the D 1
and D 2
dopamine receptors. Endocr J, 1994, 2:7–23.
Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling
molecule in the vascular system: An overview. J
Cardiovasc Pharmacol, 1999, 34:879–886.
Jahn R, Lang T, Südhof T. Membrane fusion. Cell, 2003,
112:519–533.
Kable JW, Murrin LC, Bylund DB. In Vivo Gene Modification
Elucidates Subtype-Specific Functions of α 2
-Adrenergic
Receptors. J Pharmacol Exp Ther, 2000, 293:1–7.
Kalamida D, Poulas K, Avramopoulou V, et al. Muscle and neuronal
nicotinic acetylcholine receptors structure function and
pathogenicity. FEBS J, 2007, 274:3799–3845.
Karlin A, Akabas MH. Toward a structural basis for the function
of nicotinic acetylcholine receptors and their cousins. Neuron,
1995, 15:1231–1244.
Kennedy B, Elayan H, Ziegler MG. Glucocorticoid elevation of
mRNA encoding epinephrine-forming enzyme in lung. Am J
Physiol, 1993, 265:L117–L120.
Kohout TA, Lefkowitz RJ. Regulation of G protein–coupled
receptor kinases and arrestins during receptor desensitization.
Mol Pharmacol, 2003, 63:9–18.
Kubista H, Boehm S. Molecular mechanisms underlying the
modulation of exocytoxic noradrenaline release via presynaptic
receptors. Pharmacol Ther, 2006, 112:213–242.
Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase
activity and gene expression. J Neurochem, 1996, 67:
443–462.
Kunze WAA, Furness JB. The enteric nervous system and regulation
of intestinal motility. Annu Rev Physiol, 1999, 61:117–142.
Lakhlani PP, MacMillan LB, Guo TZ, et al. Substitution of a
mutant α 2A
-adrenergic receptor via “hit and run” gene targeting
reveals the role of this subtype in sedative, analgesic, and
SECTION II
NEUROPHARMACOLOGY
anesthetic-sparing responses in vivo. Proc Natl Acad Sci USA,
1997, 94:9950–9955.
Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine
receptors as CNS drug targets. Pharmacol Ther, 2008,
117:232–243.
Lefkowitz RJ. G protein–coupled receptors: III. New roles for
receptor kinases and β-arrestins in receptor signaling and
desensitization. J Biol Chem, 1998, 273:18677–18680.
Lefkowitz RJ. The superfamily of heptahelical receptors. Nature
Cell Biol, 2000, 2:E133–E136.
Lugardon K, Raffner R, Goumon Y, et al. Antibacterial and antifungal
activities of vasostatin-1, the N-terminal fragment of
chromogranin A. J Biol Chem, 2000, 275:10745–10753.
Lynch GS, Ryall JG. Role of β-adrenoceptor signaling in skeletal
muscle: Implications for muscle wasting and disease.
Physiol Rev, 2008, 88:729-767.
Ma YC, Huang XY. Novel signaling pathways through the
β-adrenergic receptors. Trends Cardiovasc Med, 2002, 12:
46–49.
MacDermott AB, Role LW, Siegelbaum SA. Presynaptic
ionotropic receptors and the control of transmitter release.
Annu Rev Neurosci, 1999, 22:443–485.
Man in’t Veld A, Boomsma F, Lenders J, et al. Patients with
congenital dopamine β-hydroxylase deficiency: A lesson in
catecholamine physiology. Am J Hypertens, 1988, 1:
231–238.
Männistö PT, Kaakkola S. Catechol-O-methyltransferase
(COMT): Biochemistry, molecular biology, pharmacology,
and clinical efficacy of the new selective COMT inhibitors.
Pharmacol Rev, 1999, 51:593–628.
Masson J, Sagne C, Hamon M, Mestikawy SE. Neurotransmitter
transporters in the central nervous system. Pharmacol Rev,
1999, 51:439–464.
McDonald TF, Pelzer S, Trautwein W, Pelzer DJ. Regulation and
modulation of calcium channels in cardiac, skeletal, and
smooth muscle cells. Physiol Rev, 1994, 74:365–507.
Meir A, Ginsburg S, Butkevich A, et al. Ion channels in presynaptic
nerve terminals and control of transmitter release.
Physiol Rev, 1999, 79:1019–1088.
Michelotti GA, Price DT, Schwinn DA. α 1
-Adrenergic receptor
regulation: Basic science and clinical implications. Pharmacol
Ther, 2000, 88:281–309.
Miller RJ. Presynaptic receptors. Annu Rev Pharmacol Toxicol,
1998, 38:201–227.
Moncada S, Higgs A, Furchgott R. International Union of
Pharmacology nomenclature in nitric oxide research.
Pharmacol Rev, 1997, 49:137–142.
Murthy VN, Stevens CF. Synaptic vesicles retain their identity
through the endocytic cycle. Nature, 1998, 392:497–501.
Mutafova-Yambolieva VN, Hwang SF, Hao X, et al. β-nicotinamide
adenine dinucleotide is an inhibitory neurotransmitter
in visceral smooth muscle. Proc Natl Acad Sci USA,
2007.
Nagatsu T. Genes for human catecholamine-synthesizing
enzymes. Neurosci Res, 1991, 12:315–345.
Nathanson NM. Synthesis, trafficking and localization of muscarinic
acetylcholine receptors. Pharmacol Ther, 2008, 119:33–43.
Numa S, Noda M, Takahashi H, et al. Molecular structure of the
nicotinic acetylcholine receptor. Cold Spring Harbor Symp
Quant Biol, 1983, 48:57–69.